XTALPI (02228) released its annual performance with a net profit attributable to shareholders of 124 million yuan, turning losses into profits on a year-on-year basis and maintaining a leading position in the industry in the field of AI applications.

XTALPI (02228) released its annual performance as of December 31, 2025. The group achieved revenue of RMB 803 million, an increase of 201.25% year-on-year; the net profit attributable to equity holders of the company was RMB 124 million, turning losses into profits year-on-year; earnings per share were RMB 0.03. The announcement stated that the group achieved annual profit for the first time, becoming the first Hong Kong-listed company in the AI for Science field to turn a profit. The group also achieved a series of significant achievements in its business: 1) Empowering and incubating 5+ globally first-in-class/best-in-class innovative pipelines entering clinical or IND-enabling stages, covering areas such as oncology, immuno-oncology, neurodegenerative diseases, and chronic diseases; 2) Several major collaborations have been landed, with a total collaboration amount reaching hundreds of billions of RMB, firmly establishing a leading position in the industry in AI applications; 3) The number of revenue-generating customers in 2025 increased by 62% year-on-year; as of now, the group has covered 17 of the top 20 pharmaceutical companies in the world, successfully achieving multi-scenario delivery and international recognition from top customers; 4) The group has developed over 200+ industry AI models, successfully expanding new drug innovation platforms in 2025, including molecular glue, peptides, and nucleic acids, further solidifying its full-stack capability barriers; 5) The intelligent body independently advances tens of thousands of compound experiments every week, achieving R&D closed loop; 6) Successful expansion into new areas such as new materials and consumer health. These milestones mark the official entry of the group's "AI+Siasun Robot & Automation" platform value into the commercialization stage, laying a solid foundation for sustainable, high-quality growth. As of December 31, 2025, the group's total cash balance was RMB 7.069 billion, and the net proceeds from the new convertible bonds issued by the group in 2026 amounted to RMB 2.537 billion. The abundant financial reserves provide a solid guarantee for continuous research and development investment, further consolidating XTALPI's industry-leading position in the AI for Science field. During the reporting period, the group was successfully included in the MSCI China Small Cap Index, MSCI China Index, and HKEX Tech100 Index, receiving dual authoritative recognition from the international capital market in terms of investment value and industry core position.